Menu Search
Equities

Pulmonx Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4NI:FRA

Pulmonx Corp

Actions
  • Price (EUR)1.19
  • Today's Change-0.05 / -4.03%
  • Shares traded235.00
  • 1 Year change-79.66%
  • Beta0.0896
Data delayed at least 15 minutes, as of Feb 06 2026 07:07 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.

  • Revenue in USD (TTM)91.66m
  • Net income in USD-56.75m
  • Incorporated2013
  • Employees291.00
  • Location
    Pulmonx Corp700 Chesapeake DrREDWOOD CITY 94063United StatesUSA
  • Phone+1 (650) 934-2600
  • Fax+1 (302) 655-5049
  • Websitehttps://pulmonx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.